Testing effectiveness (Phase 2)Study completedNCT02121782What this trial is testingA Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)Who this might be right forInfluenza Green Cross Corporation 84
Early research (Phase 1)Ended earlyNCT03888989What this trial is testingResponse to Influenza Vaccine During PregnancyWho this might be right forInfluenza Stanford University 2
Testing effectiveness (Phase 2)Study completedNCT01991587What this trial is testingSafety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in AdultsWho this might be right forVirus DiseasesRNA Virus InfectionsRespiratory Tract Diseases+1 more Medicago 120
Testing effectiveness (Phase 2)UnknownNCT02247362What this trial is testingStudy of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 YearsWho this might be right forInfluenza VaxInnate Corporation 200
Early research (Phase 1)Study completedNCT03088904What this trial is testingGenetic and Environmental Factors in the Response to Influenza VaccinationWho this might be right forInfluenzaHealthy Stanford University 109
Large-scale testing (Phase 3)Study completedNCT05044195What this trial is testingA Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of AgeWho this might be right forInfluenza, Human Seqirus 2,044
Large-scale testing (Phase 3)Study completedNCT01711736What this trial is testingStudy to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of AgeWho this might be right forInfluenza GlaxoSmithKline 606
Testing effectiveness (Phase 2)Study completedNCT02236052What this trial is testingImmunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly PopulationWho this might be right forVirus DiseasesRNA Virus InfectionsRespiratory Tract Diseases+1 more Medicago 450
Post-approval studies (Phase 4)Study completedNCT02222870What this trial is testingSafety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza VaccineWho this might be right forInfluenza Sanofi Pasteur, a Sanofi Company 60
Large-scale testing (Phase 3)Study completedNCT03744104What this trial is testingA Clinical Trial of A Quadrivalent Influenza VaccineWho this might be right forInfluenza Shanghai Institute Of Biological Products 2,688
Large-scale testing (Phase 3)Study completedNCT02207413What this trial is testingEvaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and ChildrenWho this might be right forInfluenza GlaxoSmithKline 1,886
Early research (Phase 1)Study completedNCT03312699What this trial is testingEffects of Aging on Primary and Secondary Vaccine ResponsesWho this might be right forInfluenzaHepatitis ATyphoid+1 more Stanford University 54
Large-scale testing (Phase 3)Study completedNCT04210349What this trial is testingStudy of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of AgeWho this might be right forInfluenza Sanofi Pasteur, a Sanofi Company 7,106
Large-scale testing (Phase 3)Study completedNCT05045144What this trial is testingA Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.Who this might be right forRespiratory Syncytial Virus Infections GlaxoSmithKline 1,586
Large-scale testing (Phase 3)Study completedNCT05513053What this trial is testingStudy With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.Who this might be right forInfluenza Immunization Sanofi Pasteur, a Sanofi Company 1,308
Large-scale testing (Phase 3)Study completedNCT03704740What this trial is testingImmunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 MonthsWho this might be right forInfluenza SK Bioscience Co., Ltd. 676
Large-scale testing (Phase 3)Ended earlyNCT04137887What this trial is testingStudy to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and OlderWho this might be right forInfluenza (Healthy Volunteers) Sanofi Pasteur, a Sanofi Company 33,096
Large-scale testing (Phase 3)Study completedNCT02917304What this trial is testingEvaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and OlderWho this might be right forInfluenza, Human Green Cross Corporation 274
Large-scale testing (Phase 3)Study completedNCT03460743What this trial is testingEvaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.Who this might be right forInfluenza, Human Laboratorios Liomont 1,556
Testing effectiveness (Phase 2)Study completedNCT03233217What this trial is testingSafety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 YearsWho this might be right forInfluenza Sanofi Pasteur, a Sanofi Company 175